Infection Control in Healthcare Facilities patnadaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from patnadaily.com Daily Mail and Mail on Sunday newspapers.
Hospital Acquired Infections Therapeutic Market Size Worth $12.5 Billion By 2027: Grand View Research, Inc.
to reach USD 12.5 billion by
2027, according to a new report by Grand View Research, Inc. The market is expected
to expand at a CAGR of 2.4% from 2020 to
2027. The high prevalence of HAIs, rise in approval and launch of new drugs, and growing hospitalization due to the rise in prevalence of chronic diseases are driving the market.
Key suggestions from the report:
Antibacterial drugs dominated the drug class segment in 2019, owing to the high adoption of antibiotics as the first line of treatment for hospital-acquired infections (HAIs)
The surgical site infections (SSIs) segment held the largest market share in 2019 due to the rising number of surgical procedures and subsequent rising cases of SSIs
Antibiotics Technologies and Markets, 2025
January 12, 2021 04:38 ET | Source: Research and Markets Research and Markets Dublin, IRELAND
Dublin, Jan. 12, 2021 (GLOBE NEWSWIRE) The Antibiotics: Technologies and Global Markets report has been added to
ResearchAndMarkets.com s offering.
The global market for antibiotics should grow from $44.4 billion in 2020 to reach $65.4 billion by 2025 at a compound annual growth rate (CAGR) of 8.1% during the period of 2020-2025.
The report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals, recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control approaches, strategies and products; drugs used for symptomatic treatment and not for the elimination of the virus from the host; and details on manufacturers and suppliers of non-branded generics.
C-CAMP announces trifecta of excellence to prevent spread of infections
C-CAMP announces trifecta of excellence to prevent spread of infections
02 January 2021 | News
Image credit- Biomoneta
The Centre for Cellular and Molecular Platforms (C-CAMP) has collaborated with Applied Materials India and Biomoneta Research to develop and commercialize an industrial biotech solution to prevent the spread of infections. The solution uses Biomoneta’s innovative Zebox technology that has revolutionized the concept of air filtration and purification in infection prone settings such as Intensive Care Units (ICUs).
At a time when hospitals have become infection hotspots and 20% of hospital patients with COVID-19 are reported to have caught Hospital Acquired Infection (HAI), there is a significant need for such a technology not just in India or in Low or Middle Income Countries (LMICs) but across the world. This collaboration will undoubtedly reduce the go-to-market time while also sharpenin